DNA damage response and MCL-1 destruction initiate apoptosis in adenovirus-infected cells

  1. Andrea Cuconati1,2,4,
  2. Chandreyee Mukherjee1,2,
  3. Denise Perez2, and
  4. Eileen White1,2,3,5
  1. 1 Howard Hughes Medical Institute, Cancer Institute of New Jersey, Rutgers University, Piscataway, New Jersey 08854, USA
  2. 2 Center for Advanced Biotechnology and Medicine, Cancer Institute of New Jersey, Rutgers University, Piscataway, New Jersey 08854, USA
  3. 3 Department of Molecular Biology and Biochemistry, Cancer Institute of New Jersey, Rutgers University, Piscataway, New Jersey 08854, USA

Abstract

Expression of adenovirus E1A deregulates cell proliferation to facilitate viral DNA replication, prompting the initiation of apoptosis signaled primarily through proapoptotic BAK in productively infected cells. We demonstrate here that in uninfected cells, BAK is complexed with the anti-apoptotic BCL-2 family member Myeloid Cell Leukemia 1 (MCL-1). E1A expression during infection resulted in the specific down-regulation of MCL-1 through destabilization of the protein and loss of the mRNA. Upon loss of the MCL-1-BAK complex, BAK complexed with either BAX in proapoptotic E1B mutant adenovirus-infected cells, or with the adenovirus BCL-2 homolog E1B 19K in cells infected with the wild-type virus in which apoptosis is inhibited. Loss of MCL-1 was required to initiate the apoptotic pathway in infected cells as restoration of MCL-1 expression rescued infected cells from E1A-induced apoptosis. Analogous to E1A expression, DNA damage down-regulates MCL-1, and adenovirus infection resulted in the accumulation of phosphorylated H2AX and ataxia-telangiectasia mutant protein (ATM), hallmarks of DNA double-strand breaks. Thus, MCL-1 may function by maintaining BAK in an inactive state, and the loss of MCL-1 upon activation of the DNA damage response, perhaps through replication stress induced in virus infected cells, may be required to initiate the apoptotic response.

Keywords

Footnotes

  • Article published online ahead of print. Article and publication date are at http://www.genesdev.org/cgi/doi/10.1101/gad.1156903.

  • 4 Present address: Discovery Research, ViroPharma Incorporated, Exton, PA 19341, USA.

  • 5 Corresponding author. E-MAIL ewhite{at}cabm.rutgers.edu; FAX (732) 235-5795.

    • Accepted October 22, 2003.
    • Received September 30, 2003.
| Table of Contents

Life Science Alliance